Bayer's Consumer Health Division has launched a dedicated business unit focused on developing Precision Health products across various health categories. The company aims to empower individuals to take control of their personal health through digital solutions that provide personalised insights and novel delivery methods.
With a growing demand for healthcare personalisation, Bayer recognises the need for better self-care options that enable prediction, prevention, and improved management of health. The new Bayer Precision Health group will identify digital opportunities in consumer healthcare, collaborate with start-ups and digital health providers, and address unmet needs in core categories. Through evidence-based precision health products and global scaling of technologies, Bayer aims to bridge the gap between monitoring, diagnosis, treatment, and prevention, empowering consumers to have end-to-end control over their health.
The company has already initiated projects in the precision health space, including AI-based symptom assessment and a heart risk assessment powered by HUMA. Bayer believes that partnerships with innovative and evidence-driven companies will drive the future of precision health and transform everyday health solutions.
"As people increasingly turn to self-care to manage their everyday health, new digital tools are enabling them to make smarter choices through deeper and more precise understanding of their individual needs. With global leadership in the core categories people turn to for self-care, from cardiovascular and digestive health to pain management and immunity, Bayer will offer a wide range of precision health products and services." said David Evendon-Challis, Head of R&D and Chief Scientific Officer for the Consumer Health division of Bayer.
Click here to read the original news story.